Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2009

View Archived Issues

Shionogi-GlaxoSmithKline revises criteria for S/GSK-1349572 AIDS trial

Arete Therapeutics describes sEH inhibitors for the treatment of hypertension

Novel TRPA1 antagonists discovered at Abbott for the treatment of pain

University of Sheffield divulges new compounds for treating motor neuron diseases

PharmaMar discovers a new series of oncolytic compounds

Molecular InSight discloses carbonic anhydrase IX inhibitors for cancer therapy

New protease inhibitors for hepatitis C virus therapy reported by Enanta

Inovio and NIH enter research collaboration to develop universal influenza vaccines

Schering-Plough reports second quarter 2009 results

Oxygen to commence phase II Oxycyte trial in traumatic brain injury

AEterna reports results from two phase III cetrorelix studies in BPH

FDA approves Extavia for multiple sclerosis

NeuroSearch forms drug discovery and development alliance with Janssen

Antisense presents new data on ATL-1101 activity in prostate cancer cell lines

Lilly submits NDA in Japan for GLP-1 receptor agonist exenatide for diabetes

Onyx to progress oncology compound ONX-0801 into clinical development

Santhera acquires Juvantia and rights to fipamezole

Novel JAK2 inhibitors identified at Abbott for cancer

PDE10A inhibitors developed in Biotie/Wyeth partnership for schizophrenia

Ultra-low-molecular-weight heparin RO-14 evaluated in humans for the first time

Long-acting formulation of 2-methoxyestradiol safe in phase I study

Epigallocatechin gallate a possible treatment for Duchenne muscular dystrophy

NRX-194204 well tolerated in phase I/II solid tumors and NSCLC trial

Study finds NPI-2358-docetaxel combination feasible in non-small cell lung cancer

Phase II data on AT-101 with docetaxel in non-small cell lung cancer presented